Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Body composition and infliximab pharmacokinetics in inflammatory bowel disease
NL-OMON46317Suspended
- Sponsor
- Zuyderland
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of infliximab in inflammatory bowel disease (IBD), autoimmune colitis and Crohn's disease, sponsored by Zuyderland. Primary endpoints: Correlation between fat mass and infliximab level, Infliximab trough concentration and 1 more. Started Jan 2019; status: suspended.
02
Drugs
infliximab
03
Conditions
inflammatory bowel disease (IBD)autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on NL-OMON46317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46317.